Method of obtaining preparation for carrying out application skin test

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biotechnology, and describes method of obtaining preparation for carrying out application skin test, which includes mixing tested substance with carrier and solvent, as carrier used is gar-agar, as solvent - borate buffer pH 6.8-7.2, agar-agar in borate buffer is heated with mixing to complete dissolution of agar-agar, mixture is cooled to 40-45°C and tested substance in amount 10-50% of total volume of ready preparation is introduced, as tested substances used are their water solutions with concentrations, capable of inducing contact reactions of hypersensitivity.

EFFECT: method makes it possible to detect hypersensitivity to tested substances.

3 ex

 

The invention relates to the field of biotechnology, namely to obtain drugs for research in the field of Allergology and dermatology to determine the causal factors of hypersensitivity reactions to various compounds and multicomponent mixtures, existing in the form of aqueous solutions with low concentrations.

A known method of producing drug for conducting human patch test, based on the mixing of a test substance with a carrier and a solvent, where the media is used melted white petrolatum, and the solvent used is a mixture of distilled water, ethyl alcohol and acetone

(EN 2235557 C1, A61K 39/35, 2004)

However, the known method does not allow to detect the presence of hypersensitivity in the tested substances when carrying out human patch test.

The problem to which this invention is directed, is to develop a method, which involves the identification of hypersensitivity reactions to the tested substances in aqueous solutions with low concentrations, can cause contact hypersensitivity reactions.

The technical result of the invention is to provide a preparation for conducting human patch test, able to detect hypersensitivity to the test substances the properties.

To achieve the technical result in the method of producing drug for conducting human patch test, comprising mixing a test substance with a carrier and a solvent, according to the invention as a carrier use agar-agar, and the solvent - borate buffer pH 6,8-7,2, agar-agar in borate buffer and heated with stirring to dissolve the agar-agar, cool the mixture to 40-45°C and administered the test substance in the amount of 10-50% of the total volume of the finished product.

As the tested substance use their aqueous solutions with low concentrations, can cause contact hypersensitivity reactions.

The preparation for conducting dermal application of the test.

Solution A: 6.25 g H3BO3dissolve in 1 l of distilled water.

Solution B: 40 g Na2B4O7dissolve in 1 l of distilled water.

Solution C: mix solutions A and B in the ratio of 40:1, establish a pH of 6.8 to 7.2.

To 100 ml of solution C was added 1 g of agar-agar, heated and stirred to dissolve the agar-agar in boiling. The solution of agar is cooled to 40-45°C, add 10-50% of the total volume of the aqueous solution of the test drug is stirred until a homogeneous mass.

The invention is illustrated in the following examples the Ah.

Example 1. The preparation for the detection of hypersensitivity to Nickel ions.

Take the following ingredients:

- H3BO3;

- Na2B4O7;

agar-agar;

- distilled water;

Nickel sulfate hydrated as the test substance.

7 g of Nickel sulfate hydrated dissolved in 100 ml of distilled water.

0.625 g H3BO3dissolve in 100 ml of distilled water. 4 g of Na2B4O7dissolve in 100 ml of distilled water. The resulting solutions are mixed in a ratio of 40:1, set pH to 6.8. In 10 ml of borate buffer was dissolved under heating and stirring, 0.1 g agar-agar, cooled to 40°C. To 1 ml of the cooled solution are added 1 ml of prepared solution of Nickel sulfate.

Example 2. The preparation for the detection of hypersensitivity to allergen extract of wormwood.

Take the following ingredients:

- H3BO3;

- Na2B4O7;

agar-agar;

- distilled water;

- allergenic extract of wormwood (the 10,000 pnu/ml).

0.625 g H3BO3dissolve in 100 ml of distilled water. 4 g of Na2B4O7dissolve in 100 ml of distilled water. The resulting solutions are mixed in a ratio of 40:1, set pH to 7.2. In 10 ml of borate buffer restorati heating and stirring, 0.1 g agar-agar, cool to 45°C. To 1 ml of the cooled solution add 0.5 ml of allergenic extract of wormwood.

Example 3. The preparation for the detection of hypersensitivity to allergenic extract of Dermatophagoides pteronyssinus. Take the following ingredients:

- H3BO3;

- Na2B4O7;

agar-agar;

- distilled water;

- allergen extract of Dermatophagoides pteronyssinus (of 10,000 pnu/ml).

0.625 g H3BO3dissolve in 100 ml of distilled water. 4 g of Na2B4O7dissolve in 100 ml of distilled water. The resulting solutions are mixed in a ratio of 40:1, set pH to 7.2. In 10 ml of borate buffer was dissolved under heating and stirring, 0.1 g agar-agar, cooled to 45°C. To 1 ml of the obtained agar was added 0.25 ml of allergen extract of Dermatophagoides pteronyssinus.

The patient's skin is treated with a solution of 70% ethanol solution. In the application cell is placed 0,02 ml of the finished product with the test substance. The cell is attached to the skin with adhesive tape to ensure full contact of the drug over the entire area of the cell with the skin. In the absence of active reactions in the near future, after 48 hours remove the cell with the drug. Initial inspection of the contact areas spend 24 hours after removal of the cells. In case of detection of the contact area of hyperemia, itching, papular rash, the image is of infiltration, make a conclusion about the presence of hypersensitivity to the test substance. If during the primary inspection, the contact remains unchanged, then the monitoring continues even within 2-4 weeks, and if no changes, then make the conclusion that hypersensitivity to the test substance is absent.

The method of producing drug for conducting human patch test, comprising mixing a test substance with a carrier and a solvent, characterized in that as the carrier is used agar-agar, and the solvent - borate buffer pH 6.8 to 7.2, agar-agar in borate buffer and heated with stirring to dissolve the agar-agar, cool the mixture to 40-45°C and administered the test substance in the amount of 10-50% of the total volume of the finished product, at the same time as the tested substance use their aqueous solutions with concentrations that can cause contact hypersensitivity reactions.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns cat allergen fused proteins and application thereof. Substance of the invention involves a compositions containing a virus-like particle (VLP) or a viral particle and at least, one antigen, first of all at least, one cat antigen, and more specifically at least one cat antigen which is human allergen. In specific versions of the invention, said antigen represents cat antigen Fel d1 or its fragment covalently bound with the VLP.

EFFECT: invention can be applied for preparing vaccines first of all aimed at treatment and/or prevention of cat dander allergy and other cat antigens and allergens responses.

25 cl, 20 ex, 5 tbl, 4 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine. Currently, for differentiating nonspecific tuberculin reactions in cattle, dried purified tuberculin is used for mammals and "КАМ" with considering the sensitisation pattern by the reaction intensity. A common complex allergen is produced by protein settling from M scrofulaceum No. 12-C and M intracellulare No. 13-H strain cultures with added allergen produced from Corynebacterium xerosis N1911, in amount 1350 units of activity. The presence of coryneformic bacteria allergen in the "КАМ" composition improves the efficacy of a simultaneous dried purified tuberculin test for mammals in differentiating the nonspecific coryneformic bacteria reactions.

EFFECT: use of the declared allergen allows to prevent unreasonable slaughter, as well as further diagnostic finding expenses.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology, and can be applied for treatment of allergic rhinitis of domestic etiology. For this purpose in treatment included is allergen-specific immunotherapy with sublingual introduction of cause-significant allergen. Simultaneously hirudotherapy with application of medical leech on skin in region of oral cavity bottom projection is carried out. Procedures are carried out 2 times per week, starting from 0.1 ml 10-6 degree of dissolving of cause-significant allergen and bringing up to 0.5 ml of undissolved allergen, which after that is introduced 1 time per 2 weeks during 3 years.

EFFECT: invention allows to increase treatment efficiency due to increase of cause-significant allergen penetration into system of organs of mucosal immunity of upper airways.

1 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a pharmaceutical product for introduction of allergen that contains high-soluble solid dosage form introduced through tunica mucosa of mouth and containing matrix made by freeze drying from the solution containing 3-6.5 wt % pre-gelled starch and 3-5.5 wt % mannitol, or from the solution containing 2-10 wt % fish gelatine and 1-10 wt % mannitol; and allergen. Besides, invention concerns the method for making the specified product, a multidosage container, a set for allergy treatment, to the method of treating and applying the specified product.

EFFECT: preparation of allergen as a high-soluble uncompacted dosage form which is high-soluble, stable and low-fragile enough.

99 cl, 25 tbl, 1 ex

FIELD: medicine, pharmacology.

SUBSTANCE: method comprise salt-water extraction from raw material using Evans-Cook extraction liquid, mites cultivation during from 3 to 4 months, at temperature 25±2°C and relative air humidity 73±3%, on house dust and bristle. As initial basis, the mix of house dust mites Dermatophagoides farina or Dermatophagoides pternissinus culture and culture medium, including excrements, cast off skins, and food debris, is used. Salt-water extraction from raw material is performed during three days, after mixing it and homogenization with glass powder; the maintained incubation temperature is 2° to 10°C; the extraction material being shaken for 30 minutes three times a day with 1.5 hour intervals. Extraction completed, the supernatant liquor is decanted and centrifuged at 5000 to 6000 rpm for 30-40 minutes, then it is filtered through paper filter; in consequence sterilization through filtering, 3 to 4 months mother solution stabilisation, and bottling are carried out; the finished preparation is produced.

EFFECT: invention provides producing high effective treatment allergen in simplified process technology.

2 ex

FIELD: medicine.

SUBSTANCE: present invention refers to medicine and concerns microparticles containing sphere mainly consisting of cross-linked agarose carbohydrate and allergen covalently bonded with sphere, applied for immune system disturbance treatment. Used allergen is produced of plant pollen, specifically of timothy grass pollen. Application of specified microparticles provides effective treatment for patients suffering from allergy, as well as reduces by-effects of parenteral introduction.

EFFECT: development of effective method of allergy treatment and prevention.

9 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to conjugates of hydroxyalkyl starch and allergen, in which at least one hydroxyalkyl starch is covalent bonded with allergen for hyposensitisation. Conjugates HAS-allergen provide epitope profile comparable to natural, that enables to increase immunotherapy efficiency.

EFFECT: increasing of immunotherapy efficiency.

14 cl, 5 dwg

FIELD: veterinary microbiology.

SUBSTANCE: the innovation deals with intracutaneous injection of tuberculin at the volume of 0.2 ml followed by analyzing the reaction 72 h later. Animals at increased skin fold by 3 mm and more should be considered to be sick ones. Moreover, tuberculin should be injected at the dosage ranged 0.6-0.8 thousand IU. The innovation excludes the impact upon final result in predicting the factors of tuberculosis-free etiology and provides the liquidation of groundless slaughtering in cattle.

EFFECT: higher accuracy of diagnostics.

2 ex, 2 tbl

FIELD: medicine, in particular production of diagnostic allergen from cockroach.

SUBSTANCE: claimed method includes alkali extraction of raw materials followed by centrifugation, filtering, and sterilizing filtering of target product, wherein as raw material mixture of frozen cockroaches is used. Said mixture is crushed, then ether is added, mixture is shacked, filtered, dried to full ether evaporation, grated to produce powder. In obtained powder ether is added again, powder is dried to full ether evaporation, and alkali extraction is carried out. Extracting material is agitated and for 3 days is shacked three times daily for 30 min with 1.5 h interval and stored for these intervals at 2-10°C. After extraction supernatant is discharged, centrifuged, and after sterilizing filtering sterile allergen solution is held for 1-3 months at 2-10°C.

EFFECT: high effective preparation for diagnosis of diseases associated with sensitizing to cockroach.

1 ex

FIELD: medicine.

SUBSTANCE: method involves applying alkaline extraction from raw material. Daphnias are used as initial raw material, preliminary degreased with ethylic ether, dried up and crushed up to powder condition. The fat-free powder is extracted with 0.1 mole/l sodium hydroxide solution during 3 days at temperature of 4-8°C. Supernatant liquid is poured out after having finished extracting and protein is sedimented from alkaline extract with sodium benzoate as follows: 20 g of sodium benzoate is available in 1 l of alkaline extract, alkaline extract рН is reduced to 3.7. Sedimented benzoic acid is precipitated with the adsorbed allergen by centrifuging within 5 min at 2000 rpm. Allergen desorbed with benzoic acids by adding to acetone deposit. The mixture is stirred to completely dissolve benzoic acid and then it is places for 12-18 h into refrigerator at -20°С temperature. The solution is filtered, waiting 18-20 hours for full evaporation of acetone traces. Allergen powder is extracted during 3 days. Allergenic extract is centrifuged at 5000-6000 rpm within 30-40 minutes with sterilizing filtration following until ready form of diagnostic allergen being obtained. The produced preparation has been studied according to methodical instructions to primary experimentally-clinical approbation of new forms of allergens.

EFFECT: reduced risk of adverse side effects; high specific activity; no animal sensitization when given in the diagnostic doses.

FIELD: medicine, radiation biology.

SUBSTANCE: invention proposes a method for preparing allergenic preparation used for diagnosis of body radiation injures. Method involves irradiation of potato tubers by the dose 350-400 Gr, the following extraction of quinoid radiotoxin by extraction with ethanol followed by removing extractant in rotary evaporator and additional extraction with ethyl acetate. The final prepared fraction is subjected for chromatography and separated in the system: (a) 2% acetic acid, and (b) mixture benzene - acetic acid - water in the ratio = 2:4:1, respectively. The prepared allergenic fraction is eluted with 2% acetic acid solution and standardized by dry matter as measured for 1 mg/cm3. Also, invention proposes a method for diagnosis of body radiation injures involving intracutaneous administration of specific allergen and detection of autosensitization symptom. Diagnosis of radiation diseases is proved by the allergy index. Proposed methods provide preparing the specific radiation allergen for detection of radiosensitization of body and to carry out diagnosis of radiation disease. Invention can be used in radiation biology.

EFFECT: improved preparing method, improved method for diagnosis.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: allergen is taken as aqueous salt solution of protein polysaccharide complex of 10000 PNU activity produced by extracting dry degreased gnat of Aedes aegypti with alkaline buffer solution at pH of 8.0-8.2 with following cleaning as means for specific immunotherapy means applicable to allergic disease patients having sensitization to gnat stings. Method involves applying allergen of 10000 PNU concentration in 10-fold dilution introduced to a patient beginning from a dose of 0.2 ml with 1-2 days long pause. Supporting doses of the allergen are administered to the patients before gnat flight season with 10-12 days long pauses.

EFFECT: high effectiveness of the allergen and treatment method.

3 cl

FIELD: medicine, immunology, allergology.

SUBSTANCE: one should detect the parameters of immune state and objective anamnesis, before carrying out specific immunotherapy (SIT) with allergens one should detect IgM level (g/l), the quantity of monocytes (Mon), lymphocytes (Lymph) in total blood analysis in %, the quantity of B lymphocytes in % (CD19), immunoregulatory index (IRI) (CD4/CD8), phagocytic value in % (PhV), IgE serumal level in IU/ml, the quantity of points in evaluating accompanying nonallergic anamnesis (Point) {one point in case of one chronic disease, 2 points in case of two, etc.}, then one should calculate the changes in immunity parameters on the 7th d of SIT-therapy, obtained values should be applied in the following equation of regression (Y= -195.4 + 117.3·IgM + 10.8·Mon - 0.35·IgE - 17.1·Point + 7.8·Dlymph + 20.4·Dmon + 3·Dbl + 22.8·Diri) and calculating the possibility of complications it is necessary to perform by the following formula: P = 100/(1+Exp(-Y)).

EFFECT: higher accuracy of prediction and improved quality of therapy.

3 ex

FIELD: medicine, allergology, toxins, pharmacy.

SUBSTANCE: invention relates to recombinant allergens of insect venom and to specific methods for their preparing, in particular, antigen 5 of wasp venom allergen. Recombinant antigen 5 is prepared in bacterial cells as insoluble aggregates followed by their denaturation and transfer to a soluble monomeric allergen. Transfer is carried out by dialysis using acid buffer solution (pH = 3.5-6.5) that can comprise guanidine hydrochloride, or by using a cysteine-containing solvent. Based on describes methods the practically pure recombinant antigen 5 of wasp venom allergen is isolated and used in pharmaceutical composition for hyposensibilization of body to wasp venom allergen. Invention provides preparing protein with reduced reaction capability JgE owing to it can be used in immunotherapy in treatment of allergy.

EFFECT: improved preparing method, valuable properties of allergen.

8 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves applying alkaline extraction from raw material. Daphnias are used as initial raw material, preliminary degreased with ethylic ether, dried up and crushed up to powder condition. The fat-free powder is extracted with 0.1 mole/l sodium hydroxide solution during 3 days at temperature of 4-8°C. Supernatant liquid is poured out after having finished extracting and protein is sedimented from alkaline extract with sodium benzoate as follows: 20 g of sodium benzoate is available in 1 l of alkaline extract, alkaline extract рН is reduced to 3.7. Sedimented benzoic acid is precipitated with the adsorbed allergen by centrifuging within 5 min at 2000 rpm. Allergen desorbed with benzoic acids by adding to acetone deposit. The mixture is stirred to completely dissolve benzoic acid and then it is places for 12-18 h into refrigerator at -20°С temperature. The solution is filtered, waiting 18-20 hours for full evaporation of acetone traces. Allergen powder is extracted during 3 days. Allergenic extract is centrifuged at 5000-6000 rpm within 30-40 minutes with sterilizing filtration following until ready form of diagnostic allergen being obtained. The produced preparation has been studied according to methodical instructions to primary experimentally-clinical approbation of new forms of allergens.

EFFECT: reduced risk of adverse side effects; high specific activity; no animal sensitization when given in the diagnostic doses.

FIELD: medicine, in particular production of diagnostic allergen from cockroach.

SUBSTANCE: claimed method includes alkali extraction of raw materials followed by centrifugation, filtering, and sterilizing filtering of target product, wherein as raw material mixture of frozen cockroaches is used. Said mixture is crushed, then ether is added, mixture is shacked, filtered, dried to full ether evaporation, grated to produce powder. In obtained powder ether is added again, powder is dried to full ether evaporation, and alkali extraction is carried out. Extracting material is agitated and for 3 days is shacked three times daily for 30 min with 1.5 h interval and stored for these intervals at 2-10°C. After extraction supernatant is discharged, centrifuged, and after sterilizing filtering sterile allergen solution is held for 1-3 months at 2-10°C.

EFFECT: high effective preparation for diagnosis of diseases associated with sensitizing to cockroach.

1 ex

FIELD: veterinary microbiology.

SUBSTANCE: the innovation deals with intracutaneous injection of tuberculin at the volume of 0.2 ml followed by analyzing the reaction 72 h later. Animals at increased skin fold by 3 mm and more should be considered to be sick ones. Moreover, tuberculin should be injected at the dosage ranged 0.6-0.8 thousand IU. The innovation excludes the impact upon final result in predicting the factors of tuberculosis-free etiology and provides the liquidation of groundless slaughtering in cattle.

EFFECT: higher accuracy of diagnostics.

2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to conjugates of hydroxyalkyl starch and allergen, in which at least one hydroxyalkyl starch is covalent bonded with allergen for hyposensitisation. Conjugates HAS-allergen provide epitope profile comparable to natural, that enables to increase immunotherapy efficiency.

EFFECT: increasing of immunotherapy efficiency.

14 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: present invention refers to medicine and concerns microparticles containing sphere mainly consisting of cross-linked agarose carbohydrate and allergen covalently bonded with sphere, applied for immune system disturbance treatment. Used allergen is produced of plant pollen, specifically of timothy grass pollen. Application of specified microparticles provides effective treatment for patients suffering from allergy, as well as reduces by-effects of parenteral introduction.

EFFECT: development of effective method of allergy treatment and prevention.

9 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine, pharmacology.

SUBSTANCE: method comprise salt-water extraction from raw material using Evans-Cook extraction liquid, mites cultivation during from 3 to 4 months, at temperature 25±2°C and relative air humidity 73±3%, on house dust and bristle. As initial basis, the mix of house dust mites Dermatophagoides farina or Dermatophagoides pternissinus culture and culture medium, including excrements, cast off skins, and food debris, is used. Salt-water extraction from raw material is performed during three days, after mixing it and homogenization with glass powder; the maintained incubation temperature is 2° to 10°C; the extraction material being shaken for 30 minutes three times a day with 1.5 hour intervals. Extraction completed, the supernatant liquor is decanted and centrifuged at 5000 to 6000 rpm for 30-40 minutes, then it is filtered through paper filter; in consequence sterilization through filtering, 3 to 4 months mother solution stabilisation, and bottling are carried out; the finished preparation is produced.

EFFECT: invention provides producing high effective treatment allergen in simplified process technology.

2 ex

Up!